Drug Search Results
More Filters [+]

CI-1040

Alternative Names: ci-1040, ci1040, ci 1040
Latest Update: 2024-04-29
Latest Update Note: PubMed Publication

Product Description

CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of one of the key components of this pathway (MEK1/MEK2), and thereby effectively blocks the phosphorylation of ERK and continued signal transduction through this pathway.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14613031/)

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CI-1040

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CDR0000069279

P2

Completed

Non-Small-Cell Lung Cancer|Pancreatic Cancer|Breast Cancer|Colorectal Cancer

2003-11-01

NCT00034827

P2

Completed

Non-Small-Cell Lung Cancer|Pancreatic Cancer|Breast Cancer|Colorectal Cancer

None

Recent News Events